Keyword: ARCH Venture Partners
With $46 million, Boundless is using a new understanding of amplification mutatons to create a new class of drugs to fight difficult-to-treat cancers.
Mary Rozenman, Ph.D., signs on from Aimmune as Insitro's CFO and chief business officer and Pfizer veteran Keith James, Ph.D., joins as SVP of drug discovery.
The analysis found Nexvax2 was no better than placebo at protecting patients from gluten, prompting the Arch-backed biotech to stop the study.
Encoded Therapeutics' work is based on a platform designed to overcome hurdles it has identified in the gene therapy space.
BlackThorn Therapeutics raised $76 million to push targeted treatments for mood disorders into phase 2 studies.
Verve Therapeutics is launching with $58.5 million access to CRISPR and base-editing tech and cardiologist and geneticist Sekar Kathiresan as CEO.
Vividion, which is looking to boost the number of proteins small molecules can target, will advance three programs and expand its early-stage work.
Now, Insitro is ready to share a little more—starting with a Gilead partnership worth $15 million upfront, but that could total more than $1 billion.
The goal is to genetically modify and differentiate stem cells to create cell therapies that are cloaked from the immune system.
Maze Therapeutics aims to understand how some genes provide protection against disease so that they can be targeted with drugs.